Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile Infection

NCT03931941 is registered in ClinicalTrials.gov with Rebiotix Inc. as lead sponsor.

NCT NCT03931941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03931941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile Infection
Lead sponsor
Rebiotix Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 30, 2019
Completion date
July 21, 2023
Enrollment
793 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection, communicable diseases, infection